Briacell Therapeutics Corp Stock Performance
| BCT Stock | 6.74 8.48 55.72% |
Briacell Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.99, which signifies possible diversification benefits within a given portfolio. Briacell Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Briacell Therapeutics is expected to follow. Briacell Therapeutics right now shows a risk of 9.35%. Please confirm Briacell Therapeutics jensen alpha, semi variance, day typical price, as well as the relationship between the maximum drawdown and accumulation distribution , to decide if Briacell Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Briacell Therapeutics Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Briacell Therapeutics may actually be approaching a critical reversion point that can send shares even higher in February 2026. ...more
Last Split Factor 1:10 | Dividend Date 2020-01-02 | Last Split Date 2025-08-25 |
1 | Is BriaCell Therapeutics Corp. stock supported by innovation pipeline - 2025 Key Lessons Long-Term Growth Portfolio Plans - fcp.pa.gov.br | 11/05/2025 |
2 | Pattern recognition hints at BriaCell Therapeutics Corp. upside - Weekly Trade Recap High Accuracy Trade Alerts - newser.com | 11/12/2025 |
3 | BriaCell Selected to Present Phase 2 3 Clinical Data at SABCS 2025 - Yahoo Finance Singapore | 11/18/2025 |
4 | BriaCell Therapeutics Highlights Metastatic Breast Cancer Phase 23 Data - Stock Titan | 11/25/2025 |
5 | BriaCell Unveils Promising Clinical Data at 2025 SABCS - TipRanks | 12/02/2025 |
6 | BriaCells Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout - Investing News Network | 12/09/2025 |
7 | Will BriaCell Therapeutics Corp. stock gain from strong economy - Buy Signal Daily Stock Trend Reports - DonanmHaber | 12/19/2025 |
8 | Price Target Adjustments Send BCTX Stock Tumbling - timothysykes.com | 01/13/2026 |
| Begin Period Cash Flow | 862.1 K | |
| Total Cashflows From Investing Activities | -7.6 M |
Briacell |
Briacell Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,719 in Briacell Therapeutics Corp on October 16, 2025 and sell it today you would lose (197.00) from holding Briacell Therapeutics Corp or give up 11.46% of portfolio value over 90 days. Briacell Therapeutics Corp is generating 0.193% of daily returns assuming 9.3535% volatility of returns over the 90 days investment horizon. Simply put, 83% of all stocks have less volatile historical return distribution than Briacell Therapeutics, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Briacell Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Briacell Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Briacell Therapeutics Corp, and traders can use it to determine the average amount a Briacell Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0206
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BCT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 9.35 actual daily | 83 83% of assets are less volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Briacell Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Briacell Therapeutics by adding it to a well-diversified portfolio.
Briacell Therapeutics Fundamentals Growth
Briacell Stock prices reflect investors' perceptions of the future prospects and financial health of Briacell Therapeutics, and Briacell Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Briacell Stock performance.
| Return On Equity | -4.44 | ||||
| Return On Asset | -1.62 | ||||
| Current Valuation | 14.55 M | ||||
| Shares Outstanding | 1.88 M | ||||
| Price To Book | 2.07 X | ||||
| EBITDA | (36.63 M) | ||||
| Net Income | (26.56 M) | ||||
| Total Debt | 4.32 M | ||||
| Book Value Per Share | 7.35 X | ||||
| Cash Flow From Operations | (28.17 M) | ||||
| Earnings Per Share | (47.00) X | ||||
| Market Capitalization | 28.67 M | ||||
| Total Asset | 21.65 M | ||||
| Retained Earnings | (154.51 M) | ||||
| Working Capital | (3.81 M) | ||||
About Briacell Therapeutics Performance
By examining Briacell Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Briacell Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Briacell Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 8.7 K | 9.2 K | |
| Return On Tangible Assets | (1.53) | (1.45) | |
| Return On Capital Employed | (2.46) | (2.33) | |
| Return On Assets | (1.52) | (1.44) | |
| Return On Equity | (1.33) | (1.40) |
Things to note about Briacell Therapeutics performance evaluation
Checking the ongoing alerts about Briacell Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Briacell Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Briacell Therapeutics had very high historical volatility over the last 90 days | |
| Briacell Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (26.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Briacell Therapeutics generates negative cash flow from operations | |
| Latest headline from news.google.com: Price Target Adjustments Send BCTX Stock Tumbling - timothysykes.com |
- Analyzing Briacell Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Briacell Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Briacell Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Briacell Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Briacell Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Briacell Therapeutics' stock. These opinions can provide insight into Briacell Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.